LifeStyle
-
Nongshim's container-type smart farm goes for pilot project in Oman
SEOUL -- Nongshim, a food and beverage company in South Korea, will export a container-type vertical smart farm for a pilot project in Oman, which has launched a state smart farm initiative to decrease its reliance on food imports. Nongshim said its smart farm enables crop cultivation up to 18 times a year. Cultivation is possible immediately if only electricity and water are connected locally. This is Nongshim's first smart farm export since it formed an in-house startup team i
23 November 2022
-
CGBio unveils skin trouble care patch as first of microneedle pipeline
SEOUL -- CGBio, a total healthcare provider in South Korea, has unveiled a skin trouble care patch as the first of its microneedle pipeline. Microneedles or microneedle patches are made from a variety of materials ranging from silicon, titanium, stainless steel, and polymers to increase the diffusivity of drugs to the stratum corneum by creating micron-size pores in the skin. With the launch of its skin trouble care patch named "CGDew Dermaregen," GBio aims to release f
14 November 2022
-
HK inno.N signs CMO contract to produce clinical trial drugs for stem cell-derived organoid treatments
SEOUL -- HK inno.N, a bio-health company in South Korea, will carry out the consignment production of clinical trial drugs for stem cell-derived organoid treatments under development by Cell in Cells, a domestic bio company which has a pipeline of stem cell-derived regenerative organoid treatments for various diseases. An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic micro-anatomy. Organoids are derived from
2 November 2022
-
SK Bioscience receives $140 million CEPI fund to develop mRNA vaccine platform
SEOUL -- SK Bioscience, the developer of South Korea's first homemade COVID-19 vaccine, will receive a new research fund of up to $140 million from an international foundation, which finances vaccine research projects, to push for the development of a messenger ribonucleic acid (mRNA) vaccine with the aim of establishing a research and development system that can prevent existing or unknown viruses. SK Bioscience said it has been selected by the Coalition for Epidemic Preparedne
25 October 2022
-
Samsung Biologics clinches $296 million contract from Britain's GSK for consignment production
SEOUL -- Samsung Biologics, a leading bio company in South Korea, has clinched a $296 million contract from GlaxoSmithKline (GSK), a British multinational pharmaceutical company, for the consignment production of unspecified medicines. The contract period is until December 31, 2030. In a regulatory filing on October 20, Samsung Biologics refused to disclose which drugs are commissioned to produce. Under a partnership with GSK in 2020, Samsung Biologics agreed to supply belimumab,
20 October 2022
-
Eco-friendly biofloc method used for S. Korea's first production of Asian tiger shrimps
SEOUL -- A South Korean aquafarm is ready to release fresh or live Asian tiger shrimps, which are regarded as high-end shrimp ingredients for various grilled shrimp dishes and imported in frozen form from Southeast Asian countries such as Vietnam and Thailand. It was the first commercial farming of black tiger shrimps in South Korea. Asian tiger shrimps identified by black stripes across the dorsal side of the tail are native to Indo-Pacific, Asian, and Australian waters. They prefe
17 October 2022
-
Researchers celebrate completion of new underground astroparticle research facility
SEOUL -- South Korean researchers celebrated the completion of a new world-class astroparticle research facility located 1,000 meters underground in a remote mountain area for noise-free experiments to explain the origin and structure of the universe by detecting dark matter and neutrinos. The state project to build Yemi Lab in a 989-meter-high mountain in Jeongseon, a county about 140 kilometers (87 miles) southeast of Seoul, cost some 30.85 billion won ($21.78 million) to build a
5 October 2022
-
CGBio secures firm foothold to sell synthetic bone graft material in North America
SEOUL -- CGBio, a total healthcare provider in South Korea, has secured a firm foothold for the sale of its synthetic bone graft material used clinically for spine, orthopedic, trauma and dental applications in North America through a license-out and finished product supply contract with Orthofix, a U.S. medical device company. CGBio's Novosis, approved for use in South Korea, Southeast Asia, Mexico and India, is a recombinant human bone morphogenetic protein-2 (rhBMP-2) bon
5 October 2022
